LSU Health New Orleans Announces Non-Addictive, Non-Toxic Painkiller

LSU Health New Orleans announces the discovery and clinical development of a new non-opioid therapeutic candidate for the treatment of acute, chronic, and neuropathic pain, as well as migraine headaches, that lacks the organ toxicity and addictive potential of other currently available pain therapies.

The team that found this novel treatment was directed by Dr. Nicolas Bazan, Boyd Professor and Director of the Neuroscience Center of Excellence.

With great enthusiasm, Dr. Bazan says: “Our research offers hope for millions suffering from pain while also providing a pathway to counteract addiction. This extensive study also validates the entrepreneurial and translational potential of the research conducted at the LSU Health Neuroscience Center of Excellence. By understanding and harnessing the brain’s own mechanisms, we are addressing the opioid crisis by developing safer, more effective pain management solutions for people worldwide.”

The patents that define the family of non-opioid pain medicines have been exclusively licensed by LSU Health New Orleans to South Rampart Pharma in order to bring this novel, safer painkiller to market. The primary drug, SRP-001, has currently proven to be safe and effective in Phase 1 human clinical studies thanks to funding from institutional, federal, and venture capital sources. As a result of SRP-001’s potential to fill a significant medical need, the FDA has granted it Fast Track designation for the treatment of acute pain, guaranteeing that the medication will move forward into more thorough clinical trials.

To learn more about this new drug candidate or Dr. Bazan, visit the LSU Health New Orleans Neuroscience Center of Excellence.

SOURCE LSU Health New Orleans